)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Novakand Pharma (NOVKAN) investor relations material
Novakand Pharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary28 Aug, 2025
Executive summary
Positive top-line results reported from the KANDOVA phase Ib/IIa study in ovarian cancer, meeting both primary and secondary objectives.
Successful pre-IND meeting with the FDA for KAND567 in ST-elevation myocardial infarction, with positive regulatory feedback.
WHO granted International Non-proprietary Names (INN) for KAND567 (rugocrixan) and KAND145 (fosrugocrixan), marking a first for small molecule CX3CR1 antagonists.
Termination of the letter of intent with Recardio Inc. post-period due to challenging capital markets and inability to secure external financing.
Company name change to Novakand Pharma planned for September.
Financial highlights
Net sales were SEK 0 million for both the quarter and the first half, unchanged year-over-year.
R&D expenses decreased to SEK 4.8 million in Q2 (from SEK 9.7 million) and SEK 15.8 million for H1 (from SEK 21.2 million).
Operating loss for Q2 was SEK -6.3 million (improved from SEK -11.4 million); H1 operating loss was SEK -19.5 million (from SEK -24.7 million).
Net loss for Q2 was SEK -6.3 million (from SEK -10.9 million); H1 net loss was SEK -19.2 million (from SEK -23.9 million).
Cash flow from operations improved to SEK -9.8 million in Q2 (from SEK -14.4 million); H1 cash flow was SEK -18.8 million (from SEK -29.7 million).
Cash and cash equivalents at June 30, 2025, were SEK 27.6 million (down from SEK 75.7 million a year earlier).
Equity at June 30, 2025, was SEK 43.1 million (from SEK 83.0 million); equity/assets ratio was 92% (up from 87%).
Outlook and guidance
Current cash is expected to fund operations until Q1 2026; new activities require additional capital from licensing or investors.
Company is revisiting its business plan and exploring new out-licensing and business development opportunities.
FRACTIVE phase IIb study in acute myocardial infarction planned to start in 2026, pending capital injection.
What are the next steps after Recardio LOI termination?
How will FRACTIVE study funding be secured?
What's next for KAND567 in ovarian cancer?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Novakand Pharma earnings date
Q3 202521 Nov, 2025
Next Novakand Pharma earnings date
Q3 202521 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Kancera AB is a Swedish biotechnology company focusing on developing pharmaceuticals for the treatment of severe diseases, particularly cancer and inflammatory conditions. The company's efforts are primarily directed towards creating small molecule drug candidates that target disease-promoting immune and cancer cells, specifically utilizing the fractalkine axis. Kancera's work is divided into two main areas: Pharmaceutical Development and Industrial Research and Development (R&D). Solna, Stockholm, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage